Lucid Ebitda from 2010 to 2024
| LUCD Stock | USD 0.79 0.02 2.60% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -49.8 M | Current Value -47.3 M | Quarterly Volatility 19.1 M |
Check Lucid Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lucid Diagnostics' main balance sheet or income statement drivers, such as Interest Expense of 436.8 K, Tax Provision of 0.0 or Depreciation And Amortization of 2.7 M, as well as many indicators such as Price To Sales Ratio of 23.04, Dividend Yield of 0.0 or Days Sales Outstanding of 12.77. Lucid financial statements analysis is a perfect complement when working with Lucid Diagnostics Valuation or Volatility modules.
Lucid | Ebitda |
Latest Lucid Diagnostics' Ebitda Growth Pattern
Below is the plot of the Ebitda of Lucid Diagnostics over the last few years. It is Lucid Diagnostics' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lucid Diagnostics' overall financial position and show how it may be relating to other accounts over time.
| Ebitda | 10 Years Trend |
|
Ebitda |
| Timeline |
Lucid Ebitda Regression Statistics
| Arithmetic Mean | (15,409,960) | |
| Coefficient Of Variation | (123.90) | |
| Mean Deviation | 15,603,281 | |
| Median | (4,420,544) | |
| Standard Deviation | 19,093,702 | |
| Sample Variance | 364.6T | |
| Range | 49.8M | |
| R-Value | (0.77) | |
| Mean Square Error | 157.8T | |
| R-Squared | 0.60 | |
| Significance | 0.0007 | |
| Slope | (3,301,822) | |
| Total Sum of Squares | 5104T |
Lucid Ebitda History
About Lucid Diagnostics Financial Statements
Lucid Diagnostics stakeholders use historical fundamental indicators, such as Lucid Diagnostics' Ebitda, to determine how well the company is positioned to perform in the future. Although Lucid Diagnostics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Lucid Diagnostics' assets and liabilities are reflected in the revenues and expenses on Lucid Diagnostics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Lucid Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EBITDA | -49.8 M | -47.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:Check out the analysis of Lucid Diagnostics Correlation against competitors. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 0.09 | Quarterly Revenue Growth 0.497 | Return On Assets (1.01) | Return On Equity (10.08) |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.